CG Oncology, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| CG Oncology, Inc. | CGON - NASDAQ |
$16.00-$18.00 | $19.00 | $29.00 | 20 million | 1/25/2024 |
| Morgan Stanley, Goldman Sachs, Cantor | ||||||
Co-Manager(s): LifeSci Capital | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-01-02 Terms Added 2024-01-18 Amended Prospectus 2024-01-23 | ||||||
CG Oncology, Inc. Quote & Chart - Click for current quote - CGON
IPO Boutique aggregates information on public companies and private companies, such as "CGON" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About CG Oncology, Inc. (adapted from CG Oncology, Inc. prospectus):
They are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CGON" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.